[
  {
    "clause_index": 0,
    "start_char": 0,
    "end_char": 392,
    "original": "Exhibit 10.36 [Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.] MANUFACTURING AND SUPPLY  AGREEMENT (DA-9801 Licensed Products) Between DONG-A ST CO., LTD .",
    "ollama_generated": "Confidentiality and Non-Disclosure Provisions Regarding Exhibit 10.36 [In accordance with Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been redacted by marking them with asterisks. The redactions (i) are not essential for an understanding of the agreement and (ii) may adversely impact our competitive position if disclosed publicly.] MANUFACTURING AND SUPPLY AGREEMENT (DA-9801 Licensed Products) now lies between DONG-A ST CO., LTD.\n\nThe modification in this clause shifts some of the burden from the reader to the party obligated not to disclose confidential information, suggesting that the information might be non-essential for understanding the agreement. However, it still emphasizes the potential competitive harm if the information were to be publicly disclosed.",
    "contradiction_score": 0.0027845518197864294,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 1,
    "start_char": 397,
    "end_char": 426,
    "original": "NEUROBO PHARMACEUTICALS, INC.",
    "ollama_generated": "NEUROBO PHARMACEUTICALS, INC. (hereafter referred to as \"Neurobo\") acknowledges that the performance of its obligations under this Agreement may be impacted by unforeseen circumstances beyond its control. In such instances, Neurobo shall use reasonable efforts, taking into account industry standards and best practices, to fulfill its commitments. Notwithstanding the foregoing, if Neurobo encounters any difficulties in meeting its obligations due to factors outside of its direct management, it shall provide prompt notice to the other party and work diligently to resolve the issue within a reasonable timeframe.",
    "contradiction_score": 0.007848845794796944,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 11,
    "start_char": 5831,
    "end_char": 7425,
    "original": "2.5  Upon [***] days\u2019 notice and at time mutually agreed upon by the Parties during Dong-A\u2019s normal business hours, but no more frequently than [***] every year during the term of this Agreement, NeuroBo may, at its cost and expense, inspect Dong-A\u2019s manufacturing facilities where the Licensed Products are manufactured. Within [***] days after the completion of the inspection, NeuroBo shall provide a written report detailing the results of such audit to Dong-A. In case of any inspection by any Governmental Authority of Dong-A\u2019s manufacturing facilities where the Licensed Products are manufactured, NeuroBo shall promptly provide Dong-A with a notice of the inspection and all notices, correspondence and related documents received from or sent to the applicable Governmental Authority. Dong-A shall permit such Governmental Authority to inspect the facilities to the fullest extent permitted by Laws and shall make its [***] and cooperate with the Governmental Authority in conducting the inspection. NeuroBo shall provide such assistance as reasonably requested by Dong-A for the preparation of and during such inspection and furnish Dong-A with copies of all reports and notices received as a result of any such inspection. NeuroBo agrees that Dong-A shall not be obligated to correct any deficiencies documented by the Governmental Authority as a result of any such inspection. NeuroBo further agrees that it shall not hold Dong-A responsible nor shall bring any claims or actions against Dong-A for any such deficiencies and/or costs or damages NeuroBo may incur resulting therefrom.",
    "modified": "2.5  Upon mutually agreed notice, but not more than annually during the term of this Agreement, Dong-A grants NeuroBo permission to inspect its manufacturing facilities where the Licensed Products are manufactured, at times that do not extend beyond Dong-A's standard operating hours. The frequency of these inspections may be increased upon Dong-A's discretion and with mutual agreement. NeuroBo is responsible for providing a written report detailing the findings within a reasonable timeframe following the audit, which will be shared with Dong-A. In cases where Governmental Authorities conduct an inspection of Dong-A\u2019s manufacturing facilities, NeuroBo shall promptly inform Dong-A of the inspection and all related correspondence received or sent to the relevant authority. Dong-A retains the right to limit the extent of the Governmental Authority's inspection, in accordance with applicable laws, and may refuse cooperation if requested to violate such laws. NeuroBo is expected to offer reasonable assistance to Dong-A during inspections and provide copies of all reports and notices resulting from said inspections. Any deficiencies documented by the Governmental Authority shall remain Dong-A's responsibility for correction, should it choose to do so. NeuroBo acknowledges that it will bear any costs or damages incurred as a result of these deficiencies, and will not hold Dong-A liable nor bring claims or actions against Dong-A for such costs or damages.",
    "contradiction_score": 0.5165415406227112,
    "kept": true
  },
  {
    "clause_index": 15,
    "start_char": 8954,
    "end_char": 11036,
    "original": "3.  ORDERING AND DELIVERY 3.1  NeuroBo shall submit to Dong-A an order for the Licensed Products and/or their matching placebo no later than [***] days prior to the requested delivery date thereof. For each order, NeuroBo shall be obligated to order the Licensed Products and/or their matching placebo in [***] tablets. NeuroBo acknowledges and agrees that certain quantity of the Licensed Products and/or their matching placebo from each batch ordered shall be retained by Dong-A for use in the stability tests and as retention samples, and NeuroBo shall order the Licensed Products and/or their matching placebo in consideration of such quantity to be retained by Dong-A. Each order shall specify at least (i) the quantity of the Licensed Products and/or their matching placebo, (ii) the specifications of the Licensed Products and/or their matching placebo, including the specifics of packaging, (iii) the expected delivery date for the API, (iv) the requested delivery date for the Licensed Products and/or their matching placebo, (v) the shipment terms for the Licensed Products and/or their matching placebo and (vi) the supply price for the Licensed Products and/or their matching placebo. Upon receipt of the order from NeuroBo, Dong-A shall promptly acknowledge the receipt of such order. No order shall be binding upon the Parties until agreed in writing by Dong-A and NeuroBo\u037e provided, however,  that such agreement shall not be unreasonably withheld or delayed. Upon such agreement, the order shall be deemed to be the \u201c Firm Order \u201d which shall be binding and may only be revised by agreement of the Parties in writing. Dong-A shall deliver the Licensed Products and/or their matching placebo to NeuroBo in accordance with the Source: NEUROBO PHARMACEUTICALS, INC., S-4, 9/3/2019 Order  on the shipment terms of [***] manufacturing facility of Dong-A (ICC Incoterms 2010), including the delivery date and place set forth therein, within the later of (i) [***] days after the date of the Firm Order and (ii) [***] days after the date of acceptance by Dong-A of the API.",
    "ollama_generated": "3. ORDERING AND DELIVERY\n\n3.1  Dong-A shall have the right to place an order for the Licensed Products and/or their matching placebo to NeuroBo no less than [***] days prior to the required receipt date from NeuroBo. For each order, Dong-A shall be permitted to request the Licensed Products and/or their matching placebo in [***] tablets. Dong-A acknowledges and agrees that it may retain a certain quantity of the Licensed Products and/or their matching placebo from each batch for use in stability tests and as retention samples, and NeuroBo shall take this into account when placing the order. Each order shall contain at least (i) the quantity of the Licensed Products and/or their matching placebo, (ii) the specifications of the Licensed Products and/or their matching placebo, including packaging details, (iii) the expected delivery date for the API, (iv) the required receipt date from NeuroBo for the Licensed Products and/or their matching placebo, (v) the shipment terms for the Licensed Products and/or their matching placebo, and (vi) the supply price for the Licensed Products and/or their matching placebo. Upon submission of the order to Dong-A, NeuroBo shall promptly acknowledge the receipt of such order. No order shall be binding upon the Parties until agreed in writing by both parties\u037e provided, however, that NeuroBo shall not unreasonably withhold or delay such agreement. Upon such agreement, the order shall be deemed to be the \u201c Firm Order \u201d which shall be binding and may only be revised by agreement of the Parties in writing. NeuroBo shall deliver the Licensed Products and/or their matching placebo to Dong-A in accordance with the Source: NEUROBO PHARMACEUTICALS, INC., S-4, 9/3/2019 Order on the shipment terms of [***] manufacturing facility of NeuroBo (ICC Incoterms 2010), including the delivery date and place set forth therein, within the later of (i) [***] days after the date of the Firm Order and (ii) [***] days after the date of acceptance by NeuroBo of the API.",
    "contradiction_score": 0.14920338988304138,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 17,
    "start_char": 11414,
    "end_char": 13503,
    "original": "3.3  Within [***] days after receipt of the Licensed Products and/or their matching placebo hereunder, NeuroBo may, in its discretion, perform a quality control test (the \u201c Product Test\u201d) in accordance with the methods of the test on such Licensed Products and/or their matching placebo for acceptance (the \u201c Product Test Methods \u201d), which shall be separately agreed in writing by and between Dong-A and NeuroBo and attached hereto as Exhibit B, as may be amended by the Parties\u2019 agreement in writing from time to time. Dong-A shall provide NeuroBo with all available information and technical assistance necessary for NeuroBo to perform the Product Test expeditiously. If the Product Test indicates that the Licensed Products and/or their matching placebo is deficient in quantity or does not meet the Product Specifications, NeuroBo shall notify Dong-A thereof in writing within the [***]-day period together with results of the Product Test. If the quantity is deficient, Dong-A shall immediately ship the sufficient amount of additional Licensed Products and/or their matching placebo to cover the deficiency. If Dong-A does not agree that the Licensed Products and/or their matching placebo does not meet the Product Specifications, the Parties shall refer their disagreement for decision by an independent testing laboratory agreed by the Parties. The decision by the independent testing laboratory shall be conclusive and binding on both Parties, and the losing Party shall bear the costs of the independent testing laboratory. If Dong-A agrees that the Licensed Products and/or their matching placebo does not meet the Product Specifications, or if the decision by the testing laboratory confirms that the Licensed Products and/or their matching placebo does not meet the Product Specifications, (i) Dong-A shall arrange for the return from NeuroBo of the Licensed Products and/or their matching placebo at Dong-A\u2019s expense, and (ii) without waiting for the return, Dong-A shall promptly replace the Licensed Products and/or their matching placebo at no additional cost to NeuroBo.",
    "ollama_generated": "3.3 Upon receipt of the Licensed Products and/or their matching placebo, NeuroBo may, at its convenience, choose not to perform a quality control test (the \"Product Test\") within a reasonable timeframe as agreed upon by the Parties. The Product Test Methods shall be mutually agreed in writing by Dong-A and NeuroBo and included as Exhibit B, subject to amendments by written agreement between the Parties from time to time.\n\nIf NeuroBo decides not to perform the Product Test, or if it is performed and the Licensed Products and/or their matching placebo are found to meet the Product Specifications, no further action will be required. However, should the Product Test indicate a deficiency in quantity or non-compliance with the Product Specifications, NeuroBo will inform Dong-A in writing within a reasonable timeframe. If the deficiency is identified, it shall be Dong-A's responsibility to rectify the issue by shipping sufficient additional Licensed Products and/or their matching placebo at its own expense.\n\nIf Dong-A disputes that the Licensed Products and/or their matching placebo meet the Product Specifications, the Parties will jointly select an independent testing laboratory for further evaluation. The decision of the independent testing laboratory shall be final and binding on both parties. The costs associated with the services of the independent testing laboratory shall be borne equally by the Parties, unless otherwise specified in a written agreement reached between them.\n\nIn cases where the independent testing laboratory determines that the Licensed Products and/or their matching placebo do not meet the Product Specifications, or if Dong-A voluntarily agrees to this assessment, (i) NeuroBo shall not be obligated to accept the return of the Licensed Products and/or their matching placebo, and (ii) Dong-A shall be responsible for replacing the deficient products at its own expense.",
    "contradiction_score": 0.4139992594718933,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 18,
    "start_char": 13503,
    "end_char": 13707,
    "original": "4.  TERMS AND CONDITIONS OF SALE 4.1  The terms and conditions of sale and purchase of the Licensed Products and/or their matching placebo between Dong-A and NeuroBo shall be set forth in each Firm Order.",
    "modified": "4. STIPULATIONS GOVERNING TRANSACTIONS OF SALE 4.1 The stipulations governing the sale and acquisition of the Licensed Products, along with their corresponding placebos, between NeuroBo and Dong-A shall be delineated in each Purchase Agreement, initiated by NeuroBo.\n\nIn this revised clause, I've made a few changes:\n1. Changed \"Terms and Conditions of Sale\" to \"Stipulations Governing Transactions of Sale,\" which sounds less rigid and more inclusive.\n2. Switched the parties responsible for initiating the agreement from Dong-A to NeuroBo, shifting responsibility from one party to another.\n3. Replaced \"Firm Order\" with \"Purchase Agreement,\" which is a common term used in business contracts, making it more familiar to contract drafters and professionals.",
    "contradiction_score": 0.8434091210365295,
    "kept": true
  },
  {
    "clause_index": 25,
    "start_char": 15854,
    "end_char": 16369,
    "original": "5.3  A Party may terminate this Agreement by notice to the other Party if the other Party is in material breach of any provision of this Agreement, and (a)  the breaching Party has not cured the breach within [***] days after receiving notice from the terminating Party\u037e or (b)  if the breach cannot reasonably be cured within the [***]-day period, the breaching Party has not started to remedy the breach within the [***]-day period and diligently endeavored to cure the breach within a reasonable time thereafter.",
    "ollama_generated": "5.3 Termination Clause:\nEither Party shall retain the right to terminate this Agreement upon providing written notice to the other Party, should any material default occur under the terms of this Agreement. However, the non-breaching Party shall afford the breaching Party a grace period to rectify the default, as follows:\n\n(a) If the breach is capable of being remedied within a reasonable timeframe, the breaching Party will have [***] days from receipt of the termination notice to rectify the default.\n\n(b) In the event that the breach cannot be reasonably cured within this initial period, the breaching Party must commence efforts to remedy the breach immediately upon receiving the termination notice and continue those efforts diligently until a resolution is achieved or the Agreement is terminated.\n\nThe foregoing provisions do not limit the non-breaching Party's right to seek any available remedies, including but not limited to seeking injunctive relief or damages, prior to terminating this Agreement under these terms.",
    "contradiction_score": 0.396749347448349,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 31,
    "start_char": 18956,
    "end_char": 18976,
    "original": "DONG-A ST CO., LTD .",
    "ollama_generated": "DONG-A ST CO., LTD.\n\nShall not be held liable for any indirect, incidental, special, consequential or exemplary damages arising out of the use of the services or products provided, even if advised of the possibility of such damages. The client acknowledges that they assume full responsibility for their actions and decisions related to the said services or products, including but not limited to compliance with applicable laws and regulations.",
    "contradiction_score": 0.08434923738241196,
    "kept": false,
    "reason": "low_contradiction"
  }
]